Clinical Trial Update: Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in patients with metastatic, recurrent, or locally advanced cancers associated with BRCA1/BRCA2, POLD1, or POLE mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-03